MapLight Therapeutics officer proposes $7.26M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. (MPLT) officer Christopher A. Kroeger filed notice of a proposed sale of 236,470 common shares, with an approximate sale date of May 4, 2026 and aggregate market value of $7,259,629.00.
The shares were acquired upon vesting of restricted stock units from July 5, 2024 through April 1, 2026. Sales are to be made pursuant to a previously signed/adopted Rule 10b5-1 selling plan dated December 29, 2025.
The notice also lists sales of 9,135 shares for gross proceeds of $246,020.99 on April 15, 2026, and 10,052 shares for gross proceeds of $275,140.33 on April 16, 2026.
Key Figures
Key Terms
Rule 10b5-1 selling plan regulatory
restricted stock units financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior sales by Christopher A. Kroeger does the MPLT notice list?
AI-generated analysis. How Rhea-AI works. Not financial advice.